Indian stock markets opened flat on Friday, striking a balance between the bear and bull gangs in the market. The Nifty 50 ...

The NSE Nifty 50 ended 0.45% higher at 23,591.95, while the BSE Sensex closed 0.41% up at 77,606.43 on Thursday.

Indian pharma stocks fell for the third consecutive session amid concerns of potential US tariffs on pharmaceutical imports.

This will continue to spur growth. We’ll effectively be charging a 25 per cent tariff,” US President Donald Trump said on ...

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, ...

The growth of the India generic drugs market is supported by proactive government policies aimed at bolstering the pharmaceutical sector. Initiatives such as the “Make in India” campaign and ...

Cipla faces headwinds but remains resilient with strong product portfolio, robust earnings growth potential, and reasonable ...

Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 ...

The NSE Nifty 50 ended 111.55 points or 0.5% higher at 22,508.75, while the BSE Sensex closed 341.04 points or 0.46% up at 74 ...

NECTAR, a nonprofit focused on accelerating the protein transition through sensory research, has released Taste of the Industry 2025, the most extensive public dataset assessing the taste of ...

The company’s latest initiative saw the donation of a state-of-the-art Reverse Osmosis (RO) plant to the Barampola community in the Paduwasnuwara Western Divisional Secretariat. The initiative ensures ...

The company plans to sell these products in the domestic market as well as export to markets like Latin America, US, and Africa. The Chengalpattu facility is GCPL’s 31st manufacturing plant.